126 related articles for article (PubMed ID: 23359195)
1. Evaluation of serum concentrations of vascular endothelial growth factor (VEGF) in breast cancer patients.
Hodorowicz-Zaniewska D; Kibil W; Małek A; Szpor J; Kulig J; Sztefko K
Pol J Pathol; 2012 Dec; 63(4):255-60. PubMed ID: 23359195
[TBL] [Abstract][Full Text] [Related]
2. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
5. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
6. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
7. Serum vascular endothelial growth factors a, C and d in human breast tumors.
Gisterek I; Matkowski R; Lacko A; Sedlaczek P; Szewczyk K; Biecek P; Halon A; Staszek U; Szelachowska J; Pudelko M; Bebenek M; Harlozinska-Szmyrka A; Kornafel J
Pathol Oncol Res; 2010 Sep; 16(3):337-44. PubMed ID: 19821158
[TBL] [Abstract][Full Text] [Related]
8. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
9. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
Heer K; Kumar H; Read JR; Fox JN; Monson JR; Kerin MJ
Clin Cancer Res; 2001 Nov; 7(11):3491-4. PubMed ID: 11705867
[TBL] [Abstract][Full Text] [Related]
10. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
[TBL] [Abstract][Full Text] [Related]
11. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
12. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
[TBL] [Abstract][Full Text] [Related]
13. Correlation of serum intercellular adhesion molecule 1 and vascular endothelial growth factor with tumor grading and staging in breast cancer patients.
Haghi AR; Vahedi A; Shekarchi AA; Kamran A
J Cancer Res Ther; 2017; 13(2):257-261. PubMed ID: 28643744
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.
Molina R; Augé JM; Escudero JM; Filella X; Zanon G; Pahisa J; Farrus B; Muñoz M; Velasco M
Tumour Biol; 2010 Jun; 31(3):171-80. PubMed ID: 20361287
[TBL] [Abstract][Full Text] [Related]
15. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.
Cañizares F; Sola J; Pérez M; Tovar I; De Las Heras M; Salinas J; Peñafiel R; Martínez P
Tumour Biol; 2001; 22(5):273-81. PubMed ID: 11553856
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
Gasparini G; Toi M; Gion M; Verderio P; Dittadi R; Hanatani M; Matsubara I; Vinante O; Bonoldi E; Boracchi P; Gatti C; Suzuki H; Tominaga T
J Natl Cancer Inst; 1997 Jan; 89(2):139-47. PubMed ID: 8998183
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer.
Zajkowska M; Lubowicka E; Malinowski P; Szmitkowski M; Ławicki S
Acta Biochim Pol; 2018 Dec; 65(4):621-628. PubMed ID: 30543720
[TBL] [Abstract][Full Text] [Related]
19. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and Prognostic Performance of Serum Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor 2, and Osteopontin for Gastrointestinal Cancers.
Jiang L; Hochwald S; Deng S; Chen Y; Tan C; Zhong Q; Huang H
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
